Cancer Family
Stromal Neoplasm
CI-CAN-00000360Explore in graph →
Non-malignant52 active trials2 approved drugs89 evidence items
- NCIt
- C6781
Loading cancer entity…
Cancer Family
CI-CAN-00000360Explore in graph →
Clinical trials
355 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03556384 | Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST) | completed | Phase 2 | 23 | Adam Burgoyne, MD, PhDOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT03944304 | Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib. | completed | Phase 2 | 40 | Asan Medical CenterOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT04633122 | A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib | completed | Phase 2 | 108 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT04258956 | A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy(AXAGIST) | completed | Phase 2 | 58 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT01907607 | Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib(CYCLIGIST) | completed | Phase 2 | 29 | Institut BergoniéOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT04282980 | A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST) | completed | Phase 2 | 39 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 1 | Mar 3, 2025 | clinicaltrials |
| NCT02401815 | CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 51 | Cogent Biosciences, Inc.INDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT00780494 | Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma | completed | Phase 2 | 35 | Stanford UniversityOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT03241745 | A Study of Nivolumab in Selected Uterine Cancer Patients | completed | Phase 2 | 35 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT01863745 | Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment | completed | Phase 2 | 15 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 19, 2024 | clinicaltrials |
| NCT01294202 | A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST | completed | Phase 2 | 26 | Astex Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT03926936 | FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study(FUCHSia) | completed | Phase 2 | 17 | Frederic AmantOTHER | 2 | May 28, 2024 | clinicaltrials |
| NCT02500797 | Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery | completed | Phase 2 | 164 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT00764595 | Imatinib Mesylate in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor(GISTs) | completed | Phase 2 | 5 | Translational Research Center for Medical Innovation, Kobe, Hyogo, JapanOTHER | 1 | Jul 21, 2023 | clinicaltrials |
| NCT00769782 | Surgery in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor(GISTs) | completed | Phase 2 | 6 | Translational Research Center for Medical Innovation, Kobe, Hyogo, JapanOTHER | 1 | Jul 21, 2023 | clinicaltrials |
| NCT04254939 | A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor | completed | Phase 1 / Phase 2 | 65 | CStone PharmaceuticalsINDUSTRY | 1 | Apr 27, 2023 | clinicaltrials |
| NCT02638766 | Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST(REGISTRI) | completed | Phase 2 | 15 | Grupo Espanol de Investigacion en SarcomasOTHER | 3 | Mar 27, 2023 | clinicaltrials |
| NCT02712112 | A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs | completed | Phase 2 | 51 | Asan Medical CenterOTHER | 1 | Jan 4, 2023 | clinicaltrials |
| NCT03609424 | PDR001 Plus Imatinib for Metastatic or Unresectable GIST | completed | Phase 1 / Phase 2 | 39 | Asan Medical CenterOTHER | 1 | Jan 3, 2023 | clinicaltrials |
| NCT02880020 | Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery | completed | Phase 2 | 36 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT02216578 | Ph II CABOGIST in GIST | completed | Phase 2 | 51 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | Jul 15, 2021 | clinicaltrials |
| NCT01275222 | Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors | completed | Phase 1 / Phase 2 | 117 | Novartis PharmaceuticalsINDUSTRY | 4 | Jun 25, 2021 | clinicaltrials |
| NCT00028002 | Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor | completed | Phase 2 | 63 | National Cancer Institute (NCI)NIH | 1 | Oct 26, 2020 | clinicaltrials |
| NCT01068769 | Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor | completed | Phase 2 | 34 | Suzanne George, MDOTHER | 1 | Aug 24, 2020 | clinicaltrials |
| NCT02015065 | Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors | completed | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Mar 30, 2020 | clinicaltrials |
| NCT02257541 | BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) | completed | Phase 1 / Phase 2 | 16 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 30, 2020 | clinicaltrials |
| NCT01440959 | Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258 | completed | Phase 2 | 30 | Asan Medical CenterOTHER | 1 | Jan 18, 2020 | clinicaltrials |
| NCT02889328 | Phase II Study of Regorafenib Continuous Dosing of Regorafenib in Patients With GISTs | completed | Phase 2 | 25 | Asan Medical CenterOTHER | 1 | Jan 9, 2020 | clinicaltrials |
| NCT00278876 | Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation | completed | Phase 2 | 47 | Asan Medical CenterOTHER | 1 | Jan 7, 2020 | clinicaltrials |
| NCT02607332 | Paclitaxel in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and Sunitinib | completed | Phase 2 | 25 | Asan Medical CenterOTHER | 1 | Jan 7, 2020 | clinicaltrials |
| NCT03440515 | Management of Imatinib-associated Severe Skin Rash in Patients With Gastrointestinal Stromal Tumor | completed | Phase 2 | 29 | Asan Medical CenterOTHER | 0 | Jan 7, 2020 | clinicaltrials |
| NCT02931929 | MITIGATE-NeoBOM: A Study to Evaluate 68Ga- NeoBOMB1 in Patients With Advanced TKI-treated GIST Using PET/CT | completed | Phase 1 / Phase 2 | 9 | Medical University InnsbruckOTHER | 1 | Jul 19, 2019 | clinicaltrials |
| NCT00568750 | Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors | completed | Phase 2 | 47 | Swiss Cancer InstituteOTHER | 4 | Jun 17, 2019 | clinicaltrials |
| NCT01396148 | A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor | completed | Phase 2 | 6 | PfizerINDUSTRY | 3 | Mar 27, 2019 | clinicaltrials |
| NCT02606097 | Regorafenib in GIST With Secondary C-KIT Exon 17 Mutation | completed | Phase 2 | 19 | Chang Gung Memorial HospitalOTHER | 1 | Mar 21, 2019 | clinicaltrials |
| NCT00464620 | Trial of Dasatinib in Advanced Sarcomas | completed | Phase 2 | 366 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | Nov 23, 2018 | clinicaltrials |
| NCT01560260 | Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2018 | clinicaltrials |
| NCT01154452 | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma | completed | Phase 1 / Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Aug 15, 2018 | clinicaltrials |
| NCT00659360 | AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma | completed | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 2 | Jun 29, 2018 | clinicaltrials |
| NCT01874665 | A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor(GIST) | completed | Phase 2 | 45 | Ariad PharmaceuticalsINDUSTRY | 1 | May 18, 2018 | clinicaltrials |
| NCT00867113 | Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST) | completed | Phase 2 | 91 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 14, 2018 | clinicaltrials |
| NCT01210222 | Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer | completed | Phase 2 | 35 | Gynecologic Oncology GroupNETWORK | 1 | Feb 23, 2018 | clinicaltrials |
| NCT00455559 | Ph II Study of Perifosine Plus Gleevec for Patients With GIST | completed | Phase 2 | 40 | AEterna ZentarisINDUSTRY | 0 | Feb 22, 2018 | clinicaltrials |
| NCT00633295 | Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor | completed | Phase 2 | 9 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 22, 2017 | clinicaltrials |
| NCT00112463 | Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 0 | Jun 14, 2017 | clinicaltrials |
| NCT01172548 | Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST)(INV555) | completed | Phase 2 | 132 | Novartis PharmaceuticalsINDUSTRY | 12 | May 31, 2017 | clinicaltrials |
| NCT01524848 | Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib(PAGIST) | completed | Phase 2 | 72 | Scandinavian Sarcoma GroupOTHER | 5 | May 10, 2017 | clinicaltrials |
| NCT01110668 | Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST) | completed | Phase 2 | 2 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 28, 2017 | clinicaltrials |
| NCT00718562 | Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib | completed | Phase 2 | 35 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 23, 2017 | clinicaltrials |
| NCT02150213 | Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492 | completed | Phase 2 | 59 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 5, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Jul 28, 2026source: clinicaltrials